In 2012 Cizzle entered into collaboration and licence agreements with Fujirebio Diagnostics Inc, under which the companies are working together to develop a fully functional diagnostic assay based on Cizzle's technology.
Cizzle is involved in a number of academic partnerships that are designed to extend data sets, generate tools and materials and expand the knowledge base from which Cizzle conducts its operations.
Lead investors in Cizzle are the White Rose Technology Seedcorn Fund (WRTSCF), Yorkshire Cancer Research, Yorkshire Finance and The Viking Fund.
Cizzle Biotech Limited
Heslington Hall, Heslington, York, North Yorkshire, Y010 5DD
UK company 5249093